Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

Clicks: 311
ID: 117945
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Among HIV-infected patients with advanced immunosuppression, enhanced antimicrobial prophylaxis combined with ART resulted in reduced rates of death at both 24 weeks and 48 weeks without compromising viral suppression or increasing toxic effects. (Funded by the Medical Research Council and others; R …
Reference Key
j2017theenhanced Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hakim J;Musiime V;Szubert AJ;Mallewa J;Siika A;Agutu C;Walker S;Pett SL;Bwakura-Dangarembizi M;Lugemwa A;Kaunda S;Karoney M;Musoro G;Kabahenda S;Nathoo K;Maitland K;Griffiths A;Thomason MJ;Kityo C;Mugyenyi P;Prendergast AJ;Walker AS;Gibb DM; ;;
Journal The New England journal of medicine
Year 2017
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28723333
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male adolescent aged middle aged young adult Child Randomized Controlled Trial Multicenter Study drug therapy combination africa south of the sahara / epidemiology trimethoprim cd4 lymphocyte count anti-retroviral agents / therapeutic use* hiv infections / drug therapy* kaplan-meier estimate anti-infective agents / adverse effects anti-infective agents / therapeutic use* hiv infections / mortality reality trial team sulfamethoxazole drug combination / therapeutic use pmid:28723333 pmc5603269 doi:10.1056/nejmoa1615822 james hakim victor musiime aids-related opportunistic infections / prevention & control* anti-retroviral agents / adverse effects isoniazid / therapeutic use pyridoxine / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.